The use of cytokines and costimulatory molecule gene-engineered tumor
cells to enhance tumor immunogenicity and elicit curative responses ag
ainst established tumors and tumor recurrences has become an attractiv
e prospect. The immunotherapy data obtained in many experimental tumor
systems using these engineered cells are reviewed here to provide a r
ealistic assessment of the potential and limits of this technique.